Pressurized oxygen shows promise for severe COVID-19 in small trial
NCT ID NCT04358926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether breathing pure oxygen in a pressurized chamber (hyperbaric oxygen therapy) helps moderate-to-severe COVID-19 patients with low oxygen levels. Thirty adults who needed extra oxygen and had risk factors like diabetes or heart disease were enrolled. The goal was to see if this treatment could improve oxygen saturation and reduce inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amir Hadanny
Ẕerifin, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?